Expanding therapeutic opportunities for progressive uterine cancer: clinical experience
The incidence of uterine cancer in Russia increased by 28.8 % over the last 10 years. This trend is partly associated with an increasing prevalence of overweight and aging of the female population. Despite the fact that uterine cancer is limited to the uterine body in 84 % of cases, searching for ne...
Saved in:
| Main Authors: | A. G. Kedrova, S. E. Krasilnikov, A. I. Berishvili, E. A. Zvezdkina |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-05-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/940 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021-01-01) -
Microsatellite instability in endometrial cancer: the role of diagnostic methods and their clinical application. Expert consensus
by: A. S. Tyulyandina, et al.
Published: (2023-05-01) -
The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia
by: A. E. Protasova, et al.
Published: (2024-11-01) -
Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer
by: Shao-Jing Wang, et al.
Published: (2025-03-01) -
Efficacy and safety of lenvatinib and pembrolizumab in the treatment of endometrial cancer: data from routine clinical practice in Russia
by: A. A. Rumyantsev, et al.
Published: (2024-01-01)